EP4712963A2 - Kleinmolekülige p27-hemmer - Google Patents

Kleinmolekülige p27-hemmer

Info

Publication number
EP4712963A2
EP4712963A2 EP24808047.5A EP24808047A EP4712963A2 EP 4712963 A2 EP4712963 A2 EP 4712963A2 EP 24808047 A EP24808047 A EP 24808047A EP 4712963 A2 EP4712963 A2 EP 4712963A2
Authority
EP
European Patent Office
Prior art keywords
compound
pharmaceutically acceptable
group
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24808047.5A
Other languages
English (en)
French (fr)
Inventor
Robert J. Devita
Grace Y. Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concarlo Therapeutics Inc
Original Assignee
Concarlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concarlo Therapeutics Inc filed Critical Concarlo Therapeutics Inc
Publication of EP4712963A2 publication Critical patent/EP4712963A2/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP24808047.5A 2023-05-18 2024-05-15 Kleinmolekülige p27-hemmer Pending EP4712963A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363467561P 2023-05-18 2023-05-18
PCT/US2024/029543 WO2024238709A2 (en) 2023-05-18 2024-05-15 Small molecule inhibitors of p27

Publications (1)

Publication Number Publication Date
EP4712963A2 true EP4712963A2 (de) 2026-03-25

Family

ID=93520146

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24808047.5A Pending EP4712963A2 (de) 2023-05-18 2024-05-15 Kleinmolekülige p27-hemmer

Country Status (4)

Country Link
EP (1) EP4712963A2 (de)
CN (1) CN121548417A (de)
AU (1) AU2024271540A1 (de)
WO (1) WO2024238709A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1807081A1 (de) * 2004-10-29 2007-07-18 Janssen Pharmaceutica N.V. Cyclohexyldiamine als selektive alpha-1a/1d-adrenorezeptor-antagonisten zur behandlung von benigner prostata-hypertrophie und symptomen der unteren harnwege
TWI598337B (zh) * 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
ES2642109T3 (es) * 2009-12-09 2017-11-15 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
BR112017002260A2 (pt) * 2014-08-07 2017-11-21 Vitae Pharmaceuticals Inc derivados de piperazina como moduladores do receptor x do fígado

Also Published As

Publication number Publication date
WO2024238709A3 (en) 2025-05-30
CN121548417A (zh) 2026-02-17
AU2024271540A9 (en) 2025-12-11
WO2024238709A2 (en) 2024-11-21
AU2024271540A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
JP7191828B2 (ja) がん治療のための組成物および方法
KR102111704B1 (ko) Iap 단백질의 2가 억제제 및 그를 사용하는 치료 방법
EP2427441B1 (de) Pkm2-modulatoren zur krebsbehandlung
CN105008351B (zh) Cdc7抑制剂
CN114980976A (zh) 共价ras抑制剂及其用途
EP2655350B1 (de) Bicyclische pkm2-aktivatoren
CA2823401A1 (en) Therapeutic compounds and compositions
CN107108567A (zh) 极光激酶a抑制剂
WO2012167415A1 (zh) 嘧啶并嘧啶酮类化合物及其药用组合物和应用
CN101723936A (zh) 激酶抑制剂及其在药学中的用途
AU2024360599A1 (en) Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins
US20240132485A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN105611930A (zh) 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物
CN108348779A (zh) Ack1/tnk2酪氨酸激酶的抑制剂
CN108368143A (zh) 用于癌症疗法的单马来酰亚胺官能化的铂化合物
CN111093651A (zh) Ido抑制剂的无定形和结晶形式
TW201922709A (zh) 表皮生長因子受體抑制劑
AU2024271540A9 (en) Small molecule inhibitors of p27
WO2023203172A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN113773273B (zh) 苯并异噻唑类化合物及其制备方法和用途
WO2022148821A1 (en) Usp7 binding survival-targeting chimeric (surtac) molecules & uses thereof
WO2025223477A1 (zh) 并环含氮化合物、其晶型及其制备方法和用途
CN115707702A (zh) Rad51抑制剂化合物的晶型及其应用
HK40100861A (zh) 结晶形式、含有该结晶形式的组合物及使用它们的方法
HK40074236A (en) Covalent ras inhibitors and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR